305 related articles for article (PubMed ID: 24854633)
1. Identification and characterization of small molecule human papillomavirus E6 inhibitors.
Malecka KA; Fera D; Schultz DC; Hodawadekar S; Reichman M; Donover PS; Murphy ME; Marmorstein R
ACS Chem Biol; 2014 Jul; 9(7):1603-12. PubMed ID: 24854633
[TBL] [Abstract][Full Text] [Related]
2. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling simulation studies reveal new potential inhibitors against HPV E6 protein.
Ricci-López J; Vidal-Limon A; Zunñiga M; Jimènez VA; Alderete JB; Brizuela CA; Aguila S
PLoS One; 2019; 14(3):e0213028. PubMed ID: 30875378
[TBL] [Abstract][Full Text] [Related]
4. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
[TBL] [Abstract][Full Text] [Related]
5. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
Drews CM; Case S; Vande Pol SB
PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitors of the HPV16-E6 interaction with caspase 8.
Yuan CH; Filippova M; Tungteakkhun SS; Duerksen-Hughes PJ; Krstenansky JL
Bioorg Med Chem Lett; 2012 Mar; 22(5):2125-9. PubMed ID: 22300659
[TBL] [Abstract][Full Text] [Related]
7. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
[TBL] [Abstract][Full Text] [Related]
8. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting.
Griffin H; Elston R; Jackson D; Ansell K; Coleman M; Winter G; Doorbar J
J Mol Biol; 2006 Jan; 355(3):360-78. PubMed ID: 16324714
[TBL] [Abstract][Full Text] [Related]
10. Docosahexaenoic acid induces the degradation of HPV E6/E7 oncoproteins by activating the ubiquitin-proteasome system.
Jing K; Shin S; Jeong S; Kim S; Song KS; Park JH; Heo JY; Seo KS; Park SK; Kweon GR; Wu T; Park JI; Lim K
Cell Death Dis; 2014 Nov; 5(11):e1524. PubMed ID: 25393480
[TBL] [Abstract][Full Text] [Related]
11. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.
Wang H; Mo P; Ren S; Yan C
J Biol Chem; 2010 Apr; 285(17):13201-10. PubMed ID: 20167600
[TBL] [Abstract][Full Text] [Related]
12. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
Thatte J; Banks L
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
15. Identification of MicroRNAs That Stabilize p53 in Human Papillomavirus-Positive Cancer Cells.
Martínez-Noël G; Szajner P; Kramer RE; Boyland KA; Sheikh A; Smith JA; Howley PM
J Virol; 2022 Feb; 96(4):e0186521. PubMed ID: 34878887
[TBL] [Abstract][Full Text] [Related]
16. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
[TBL] [Abstract][Full Text] [Related]
17. Identification of E6AP-independent degradation targets of HPV E6.
Vats A; Thatte J; Banks L
J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
[TBL] [Abstract][Full Text] [Related]
18. A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells.
Messa L; Celegato M; Bertagnin C; Mercorelli B; Nannetti G; Palù G; Loregian A
Sci Rep; 2018 Apr; 8(1):6020. PubMed ID: 29662081
[TBL] [Abstract][Full Text] [Related]
19. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding.
Cho Y; Cho C; Joung O; Lee K; Park S; Yoon D
Antiviral Res; 2000 Sep; 47(3):199-206. PubMed ID: 10974372
[TBL] [Abstract][Full Text] [Related]
20. Warts, cancer and ubiquitylation: lessons from the papillomaviruses.
Howley PM
Trans Am Clin Climatol Assoc; 2006; 117():113-26; discussion 126-7. PubMed ID: 18528468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
